TECTONIC THERAPEUTIC, INC. Proceeds from Common Stock Issued
TECTONIC THERAPEUTIC, INC. (TECX) reported Proceeds from Common Stock Issued of $4.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2024-05-09
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of common stock for the quarter ending 2024-03-31 was $4.00K, a 69.23% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of common stock for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of common stock for the quarter ending 2023-09-30 was $73.00K, a 21.67% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of common stock for the quarter ending 2023-06-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of common stock for fiscal 2023 was $86.00K, a 57.84% decline from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of common stock for fiscal 2022 was $204.00K.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of common stock for fiscal 2019 was $129.47M, a 24.47% increase from fiscal 2018.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of common stock for fiscal 2018 was $104.01M.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 9 month as first filed | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|---|---|
| 2024-03-31 | $4.00K 10-Q · filed 2024-05-09 | $4.00K derived: sum of 2 quarters · filed 2024-05-09 | $77.00K derived: sum of 3 quarters · filed 2024-05-09 | $77.00K derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $73.00K derived: sum of 2 quarters · filed 2024-03-14 | $73.00K derived: sum of 3 quarters · filed 2024-03-14 | $86.00K 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $73.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $73.00K derived: sum of 2 quarters · filed 2023-11-09 | $86.00K 10-Q · filed 2023-11-09 | $87.00K derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $13.00K 10-Q · filed 2023-08-10 | $14.00K derived: sum of 3 quarters · filed 2024-05-09 | $74.00K derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2023-03-31 | $13.00K 10-Q · filed 2024-05-09 | $14.00K derived: sum of 2 quarters · filed 2024-05-09 | $74.00K derived: sum of 3 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $61.00K derived: sum of 2 quarters · filed 2024-03-14 | $204.00K 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $203.00K 10-Q · filed 2023-11-09 | $0.00 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $143.00K 10-Q · filed 2023-08-10 | $0.00 10-Q · filed 2022-08-09 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$204.00K 10-Q · filed 2022-11-08 | |||||
| 2021-06-30 | -$204.00K 10-Q · filed 2022-08-09 | ||||||
| 2020-03-31 | $93.63M 10-Q · filed 2021-05-13 | $93.63M derived: sum of 2 quarters · filed 2021-05-13 | |||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $129.47M 10-K · filed 2020-03-16 | |||||
| 2019-09-30 | $129.47M 10-Q · filed 2019-11-07 | ||||||
| 2018-12-31 | $104.01M 10-K · filed 2020-03-16 | ||||||
| 2018-06-25 | $104.01M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |